Correction of Disbacteriosis Disorders Accompanied by Dislipidemia

Abstract

The people having dysbacteriosis, becomes more increasing, covering nearly a half of the population of a planet. And the combination of a syndrome of angry intestines to atherosclerosis is a harbinger of such terrible forms of an illness, as a heart attack, a stroke, etc. Now there was a first of a series developed combined bifidopreparatov. This is Bifeynol containing both a microbic protivodisbakteriozny component (bifid bacteria), and the PNZhK treatment-and-prophylactic complex of the class ω-3 (Eikonol). The assessment of clinical efficiency and Bifeynol's safety at patients with SRK and an accompanying hypercholesterolemia is carried out. 20 patients with SRK with prevalence of locks are surveyed. Efficiency of carried-out therapy was estimated by means of microbiological (epidemiology and microbiology GDTs scientific research institute laboratory of GI. Gabrichevsky) and koprologichesky research a calla, the clinical and biochemical analysis of blood with definition of a lipidic range, the general analysis of blood and urine. It is established that reduction or full elimination of clinic of SRK is noted at 85% of patients. The quantity стафилококков decreased more than by 3 times, the drozhzhepodobnykh of mushrooms – by 4 times, a haemolytic intestinal stick – almost twice. Against Bifeynol's application full elimination of yodofilny flora was noted. In blood decrease in the content of urea, the general bilirubin, Alat, Asat was noted. After a four-week course of therapy Bifeynol revealed reduction of the content of the general cholesterol due to decrease in the XC LPNP whereas concentration of the XC LPVP increased.